Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17130325 | 0.82 | IDO1 (0.53) | CDC25BTAAR1MEN1POLBRAD52 | |
| SCHEMBL18391969 | 0.78 | KCNH3 (0.58) | TAAR1MEN1KMT2ARECQLMCL1 | |
| SCHEMBL18385065 | 0.76 | KCNH3 (0.46) | TAAR1 | |
| SCHEMBL25830630 | 0.76 | KCNH3 (0.46) | TAAR1 | |
| SCHEMBL18391971 | 0.76 | CDC25B (0.48) | CDC25BTAAR1CYP3A4MEN1POLB | |
| SCHEMBL13223236 | 0.76 | CDC25B (0.48) | CDC25BTAAR1CA12CA1CA2 | |
| SCHEMBL12387589 | 0.76 | SYK (0.48) | CDC25BTAAR1CYP3A4MEN1POLB | |
| SCHEMBL18385063 | 0.76 | EGFR (0.43) | EGFRITK | |
| SCHEMBL17130308 | 0.76 | EGFR (0.43) | EGFRITK | |
| SCHEMBL13343929 | 0.69 | KCNH3 (0.40) | TAAR1SIRT5SIRT1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | Akamara Therapeutics, Inc. (US) | 2020-06-25 | — | — | US | disclosed |
| US-10533059-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2020-01-14 | — | — | US | disclosed |
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2017-01-19 | — | — | US | disclosed |
| WO-2015148126-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, ADAM8, TIE1 | CDC25B 2257/4885TAAR1 2020/4885SIRT5 1575/4885 |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | CDC25B 2120/4885TAAR1 1689/4885SIRT5 1527/4885 |
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, FCGR2A, ABCB1 | CDC25B 2120/4885TAAR1 1689/4885SIRT5 1527/4885 |
| US-10533059-B2 | Targeted drug delivery through affinity based linkers | ABCG2, ADAM8, TIE1 | CDC25B 2257/4885TAAR1 2020/4885SIRT5 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.